Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
1.
Acta Neuropathol Commun ; 4(1): 52, 2016 05 18.
Article in English | MEDLINE | ID: mdl-27193329

ABSTRACT

Niemann-Pick type C (NPC) disease is a lysosomal storage disorder characterized by the occurrence of visceral and neurological symptoms. At present, the molecular mechanisms causing neurodegeneration in this disease are unknown. Here we report the altered expression and/or mislocalization of the TAR-DNA binding protein 43 (TDP-43) in both NPC mouse and in a human neuronal model of the disease. We also report the neuropathologic study of a NPC patient's brain, showing that while TDP-43 is below immunohistochemical detection in nuclei of cerebellar Purkinje cells, it has a predominant localization in the cytoplasm of these cells. From a functional point of view, the TDP-43 mislocalization, that occurs in a human experimental neuronal model system, is associated with specific alterations in TDP-43 controlled genes. Most interestingly, treatment with N-Acetyl-cysteine (NAC) or beta-cyclodextrin (CD) can partially restore TDP-43 nuclear localization. Taken together, the results of these studies extend the role of TDP-43 beyond the Amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD)/Alzheimer disease (AD) spectrum. These findings may open novel research/therapeutic avenues for a better understanding of both NPC disease and the TDP-43 proteinopathy disease mechanism.


Subject(s)
DNA-Binding Proteins/metabolism , Niemann-Pick Disease, Type C/metabolism , Acetylcysteine/pharmacology , Animals , Brain/metabolism , Brain/pathology , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Nucleus/pathology , Cells, Cultured , Disease Models, Animal , Fibroblasts/drug effects , Fibroblasts/metabolism , Fibroblasts/pathology , Humans , Intracellular Signaling Peptides and Proteins , Male , Mice, Inbred BALB C , Mice, Transgenic , Middle Aged , Neurons/drug effects , Neurons/metabolism , Neurons/pathology , Neuroprotective Agents/pharmacology , Niemann-Pick C1 Protein , Niemann-Pick Disease, Type C/drug therapy , Niemann-Pick Disease, Type C/genetics , Niemann-Pick Disease, Type C/pathology , Proteins/genetics , Proteins/metabolism , Spinal Cord/metabolism , Spinal Cord/pathology , beta-Cyclodextrins/pharmacology
2.
J Gerontol A Biol Sci Med Sci ; 70(2): 163-73, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24550352

ABSTRACT

Aging is usually accompanied by a significant reduction in muscle mass and force. To determine the relative contribution of inactivity and aging per se to this decay, we compared muscle function and structure in (a) male participants belonging to a group of well-trained seniors (average of 70 years) who exercised regularly in their previous 30 years and (b) age-matched healthy sedentary seniors with (c) active young men (average of 27 years). The results collected show that relative to their sedentary cohorts, muscle from senior sportsmen have: (a) greater maximal isometric force and function, (b) better preserved fiber morphology and ultrastructure of intracellular organelles involved in Ca(2+) handling and ATP production, (c) preserved muscle fibers size resulting from fiber rescue by reinnervation, and (d) lowered expression of genes related to autophagy and reactive oxygen species detoxification. All together, our results indicate that: (a) skeletal muscle of senior sportsmen is actually more similar to that of adults than to that of age-matched sedentaries and (b) signaling pathways controlling muscle mass and metabolism are differently modulated in senior sportsmen to guarantee maintenance of skeletal muscle structure, function, bioenergetic characteristics, and phenotype. Thus, regular physical activity is a good strategy to attenuate age-related general decay of muscle structure and function (ClinicalTrials.gov: NCT01679977).


Subject(s)
Aging/physiology , Exercise/physiology , Muscle Fibers, Skeletal/ultrastructure , Muscle, Skeletal/physiology , Adult , Aged , Biopsy, Needle , Calcium/metabolism , Exercise Test , Humans , Insulin-Like Growth Factor I/genetics , Isometric Contraction/physiology , Male , Membrane Proteins/metabolism , MicroRNAs/genetics , Microscopy, Electron, Transmission , Mitochondria, Muscle/metabolism , Muscle Fibers, Skeletal/metabolism , Muscle, Skeletal/metabolism , Muscular Atrophy/pathology , NF-E2-Related Factor 2/metabolism , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , Protein Isoforms/genetics , Proto-Oncogene Proteins/metabolism , RNA, Messenger/metabolism , RNA-Binding Proteins/metabolism , Sedentary Behavior , Sterol Regulatory Element Binding Protein 1/metabolism , Transcription Factors/metabolism , Up-Regulation/physiology , YY1 Transcription Factor/metabolism , Young Adult
5.
Int J Immunopathol Pharmacol ; 24(3): 749-59, 2011.
Article in English | MEDLINE | ID: mdl-21978686

ABSTRACT

A lack of motor neurons abolishes both neurotrophic factor secretion and contractile activity in muscle, which impairs mass, contractile properties, and fibre-type characteristics of the muscle. However, the molecular pathways that can be stimulated or repressed in the scenario of spinal cord injury remain unknown. We investigated for the first time the transcriptional profile of a young male patient 8 months after spinal cord injury. Adaptive metabolic changes of complete denervated skeletal muscle were revealed. In particular, the main molecular pathways involved include metabolic and proteolitic pathways, mitochondrial and synaptic function, calcium homeostasis, sarcomere and anchorage structures. Our data depict the molecular signalling still present in complete denervated skeletal muscle fibres a few months after spinal cord injury. These data could be of interest also to design a specific therapeutic approach aimed at the electrical-stimulation of severe atrophied skeletal muscle.


Subject(s)
Muscle, Skeletal/metabolism , Spinal Cord Injuries/genetics , Adaptation, Psychological/physiology , Adult , Biopsy , Calcium/metabolism , Gene Expression Profiling , Gene Expression Regulation/genetics , Gene Expression Regulation/physiology , Humans , Male , Mitochondria/metabolism , Muscle Denervation , Muscle, Skeletal/pathology , Sarcomeres/metabolism , Signal Transduction/genetics , Signal Transduction/physiology , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/pathology , Synapses/physiology , Thigh/pathology , Transcriptome
6.
Ann Rheum Dis ; 69(9): 1704-10, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20439287

ABSTRACT

OBJECTIVE: To evaluate the prevalence and correlates of anti-pentraxin 3 (PTX3) antibodies in systemic lupus erythematosus (SLE). METHODS: Serum samples from 130 patients with SLE, 130 age- and sex-matched healthy subjects and 130 patients with other autoimmune rheumatic diseases (oARD) were analysed by home-made ELISAs using as substrate human recombinant PTX3 and two peptides, PTX3_1 and PTX3_2, obtained from the complete protein, identified as potential antigenic sites using the Lasergene DNA program (DNA Star). Inhibition tests were performed to evaluate potential interferences between bovine serum albumin or C-reactive protein and anti-PTX3 or anti-PTX3 peptides, and between antigens and antibodies. Statistical analysis was performed using receiving operating characteristics curves, the Fisher exact test, two-tailed t test and Pearson correlations. RESULTS: Patients with SLE had higher levels and prevalence of anti-PTX3, anti-PTX3_1 and anti-PTX3_2 antibodies than patients with oARD or healthy controls (p<0.001 for all). No differences were observed between patients with oARD and healthy controls. A correlation was found between anti-PTX3 and anti-PTX3_2 antibodies (r=0.615, p<0.001). No association was observed between these antibodies and disease activity. Univariate and multivariate analyses showed that anti-PTX3 and anti-PTX3_2 antibody levels and prevalence were higher in patients without glomerulonephritis and in patients positive for antiphospholipid antibody. All inhibition tests were negative apart from PTX3 against anti-PTX3 antibody or, to a lesser extent, against anti-PTX3_2 antibody, and PTX3_2 against anti-PTX3_2 antibody, all in a dose-dependent manner. CONCLUSIONS: Anti-PTX3 antibodies are significantly prevalent in patients with SLE where they might provide protection from renal involvement. The antigenic properties of PTX3_2 peptide are similar to those of PTX3, suggesting its potential use in further analyses.


Subject(s)
Autoantibodies/blood , C-Reactive Protein/immunology , Immunoglobulin G/blood , Lupus Erythematosus, Systemic/immunology , Serum Amyloid P-Component/immunology , Adolescent , Adult , Autoimmune Diseases/immunology , Biomarkers/blood , Cohort Studies , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Male , Middle Aged , Rheumatic Diseases/immunology , Young Adult
7.
Neurol Res ; 32(1): 26-31, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20092692

ABSTRACT

OBJECTIVE: To examine the effects of 8 weeks of vibration training at different frequencies (1 and 15 Hz) on maximal isometric torque and force development in senior sportsmen, and of 1 year of heavy-resistance and vibration trainings on muscle fibers. METHODS: Seven healthy senior sportsmen (mean age: 69.0 +/- 5.4 years) performed an 8 weeks of strength training of knee extensors. Vibrations were applied vertically to the axis of movement during training. One leg of each subject was trained at a frequency of 1 Hz, while the other leg was trained at 15 Hz. Measures of isometric peak torque (at knee-angles of 60, 90 and 120 degrees ) and force development were recorded before and after training. Four sportsmen continued a year-long heavy-resistance training adding every second week a session of vibration training. After training, muscle biopsies were harvested from their quadriceps muscles and used for structural analyses. Morphometry of muscle fibers was performed by light microscopy. Immunohistochemistry using anti-MHCemb and anti-N-CAM antibodies was performed to measure potential muscle damage. Data from muscle morphometry were compared to that of a series of vastus lateralis biopsies harvested from 12 young sportsmen and four healthy elderly. RESULTS: Our results showed a significant increase in isometric peak torque at both 1 and 15 Hz vibration frequency in all three measured angles of the knee. There was no significant difference between the two frequencies, but we could find a higher increase in percentage of maximum power after the 1 Hz training. The results of force development showed a slight increase at the 1 Hz training in measured time frames from 0 to 50 and 200 ms, without statistical significance. A trend to significance was found at the 1 Hz training at the time window up to 200 ms. The 15 Hz training showed no significant changes of force development. Muscle biopsies show that the muscles of these well trained senior sportsmen contain muscle fibers which are 35% larger than those of sedentary elderly and, unexpectedly, 10% larger than those of young sportsmen. Despite 1 year of heavy resistance and vibration training, no evidence of muscle damage or denervation/reinnervation could be observed by light microscopy analyses, ATPase histochemistry and immunohistochemistry using anti-N-CAM or anti-MHC-emb antibodies. DISCUSSION: Integration of vibration to conventional strength training in elderly sportsmen induces similar improvement of isometric peak torque and force development independently from the vibration frequency after 8 weeks of training, and long-term results in the surprising evidence of hypertrophic muscle fibers larger than those of young active sportsmen. The observation that the vibration training with low frequency is safe opens the possibility to test these rehabilitation procedures in sedentary elderly.


Subject(s)
Muscle Fibers, Skeletal/physiology , Muscle Strength/physiology , Resistance Training/methods , Torque , Vibration/therapeutic use , Aged , Aged, 80 and over , Athletes , Humans , Immunohistochemistry , Knee/physiology , Muscle Fibers, Skeletal/cytology , Muscle Fibers, Skeletal/metabolism , Time Factors , Young Adult
8.
Neurol Res ; 32(1): 20-5, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19941733

ABSTRACT

OBJECTIVE: To evaluate skeletal muscle biopsy from asymptomatic patients affected with newly diagnosed colorectal cancer and to identify pathological features which may be indicative of tumor-associated muscle disorders, potentially leading to cachexia. METHODS: Patients affected with newly diagnosed colorectal cancer at clinical onset of disease underwent biopsy of the rectus abdominis muscle during elective laparoscopic tumor resection, before chemotherapeutic treatment. Morphometric analyses, ATPase histochemistry and immunohistochemical studies using antibodies directed to N-CAM and to MHC-emb, two sound makers of muscle denervation and injury-induced muscle regeneration, were performed on intraoperative muscle biopsies from ten patients. Muscle biopsies from rectus abdominis of seven subjects affected with non-neoplastic condition, which underwent laparoscopic surgery, were used as controls. RESULTS: In patients' biopsies, we observed a surprisingly high percentage of myofibers with internalized or central nuclei compared to controls (9.15 +/- 8.9 versus 0.6 +/- 0.9, p<0.0003). In addition, in the 30% of patients, small myofibers expressing the MHC-emb have been identified (0.4 +/- 0.5 positive fibers/mm(2)), while in 50% of patients, larger fibers positive for N-CAM have also been detected (0.7 +/- 1.1 positive fibers/mm(2)), suggesting that investigated muscle biopsies exhibit other evidence of muscle fiber injury/regeneration and/or denervation. Among the 10,000 analysed myofibers in control biopsies, no MHC-emb and N-CAM-positive muscle fibers have been detected. Thus, patients affected with newly diagnosed colorectal cancer at clinical onset of disease display early signs of a subclinical myopathy. DISCUSSION: Factors and mechanisms of this cancer-associated myopathy are yet unknown. The facts that the great majority of the abnormally nucleated myofibers are of the fast type and that regenerating myofibers are present, suggest a myogenic response to the colorectal cancer and not to the laparoscopic modalities of the biopsy harvesting. Follow-up of the patients will elucidate the clinical relevance of our observation, and further studies investigating the molecular mechanism underlying this early cancer-associated myopathy will hopefully provide some pathogenetic clues leading to the identification of potential specific targets for therapeutic intervention to prevent tumor cachexia.


Subject(s)
Colorectal Neoplasms/pathology , Muscular Diseases/pathology , Rectus Abdominis/pathology , Adult , Aged , Aged, 80 and over , Cell Nucleus/metabolism , Cell Nucleus/pathology , Cohort Studies , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/surgery , Female , Humans , Italy , Male , Middle Aged , Muscle Fibers, Skeletal/metabolism , Muscle Fibers, Skeletal/pathology , Muscular Diseases/metabolism , Rectus Abdominis/metabolism , Rectus Abdominis/surgery , Time Factors
9.
Autoimmun Rev ; 9(6): 449-53, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20026430

ABSTRACT

The association between malignancy and autoimmune myositis has been largely described and confirmed by numerous epidemiological studies. The temporal relationship between the two pathologic conditions can vary: malignancy may occur before, at the same time or following the diagnosis of myositis. Beside these observations, the molecular mechanisms underlying this association are still unknown, even though it has been demonstrated a possible antigenic similarity between regenerating myoblasts and some cancer cell populations. To better identify peculiar histopathologic features common to cancer and myositis, we screened muscle biopsies from patients affected with polymyositis, dermatomyositis, myositis in association to cancer, and from patients affected with newly diagnosed cancer, but without myositis. Similarly to the histopatologic features that were observed in the muscle from myositis patients, especially in those with cancer associated myositis, in patients affected with malignancy at the clinical onset of disease we observed early sign of myopathy, characterized by internally nucleated and regenerating myofibers, most of them expressing the neural cell adhesion molecule. The hypothesis that in a particular subset of individuals genetically predisposed to autoimmunity, an initial subclinical tumor-induced myopathy may result in an autoimmune myositis, represents a further intriguing link behind the association of these two conditions.


Subject(s)
Breast Neoplasms/immunology , Carcinoma/immunology , Colorectal Neoplasms/immunology , Dermatomyositis/immunology , Ovarian Neoplasms/immunology , Antigens, Neoplasm/immunology , Breast Neoplasms/complications , Breast Neoplasms/diagnosis , Breast Neoplasms/pathology , Carcinoma/complications , Carcinoma/diagnosis , Carcinoma/pathology , Colorectal Neoplasms/complications , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/pathology , Dermatomyositis/complications , Dermatomyositis/diagnosis , Dermatomyositis/pathology , Female , Humans , Muscle, Skeletal/pathology , Myoblasts/immunology , Myoblasts/pathology , Neoplastic Stem Cells/immunology , Neoplastic Stem Cells/pathology , Neural Cell Adhesion Molecules/immunology , Ovarian Neoplasms/complications , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/pathology
10.
Autoimmunity ; 42(4): 289-91, 2009 May.
Article in English | MEDLINE | ID: mdl-19811279

ABSTRACT

High levels of oxidized low-density liprotein/beta2 glycoprotein 1 (oxLDL/beta2GPI) complexes and anti-complex IgG as well as IgM have been reported in SLE. We analysed this complex and Ab against the complex in SLE patients and evaluated their relationship with clinical and serological findings, traditional risk factors for atherosclerosis, and subclinical atherosclerosis. The prevalence and the levels of the complex and of anti-complex Ab were significantly higher in systemic lupus erythematosus (SLE) patients than in normal healthy donors (NHD). The titers of oxLDL/beta2GPI were significantly higher in patients with renal involvement and previous thromboembolic episodes and were correlated with the number of risk factors for atherosclerosis, whereas they were significantly lower in patients with neurological involvement. Both IgG and IgM anti-complex Ab were associated with antiphospholipid (APL). In conclusion, the oxLDL/beta2GPI complex as well as Ab against the complex are prevalent in SLE where they seem to be involved in organ damage.


Subject(s)
Antigen-Antibody Complex/blood , Lipoproteins, LDL/blood , Lupus Erythematosus, Systemic/blood , beta 2-Glycoprotein I/blood , Adult , Antibodies, Antiphospholipid/blood , Atherosclerosis/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunoglobulin M/blood , Immunoglobulin M/immunology , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/immunology , Male , Prevalence , Risk Factors
11.
J Autoimmun ; 32(2): 79-84, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19171463

ABSTRACT

OBJECTIVE: Serum IgG antibodies (Abs) to phosphorylated ribosomal (P ribosomal) proteins have been inconsistently associated with neuropsychiatric manifestations in systemic lupus erythematosus (SLE). Our aim was to assess whether serum IgG Abs to ribosomal P proteins are associated with neuropsychiatric SLE. PATIENTS AND METHODS: We examined an inception cohort of 219 SLE patients. Neuropsychiatric SLE manifestations were characterized using the American College of Rheumatology (ACR) definition. Serum Abs to P ribosomal proteins were searched for by immunoblotting. In a subgroup of patients, Abs were investigated also in cerebrospinal fluid (CSF). RESULTS: Abs to P ribosomal proteins were detected in 45 (21%) patients, 23 of whom (51%) with neuropsychiatric involvement. Abs to P ribosomal protein were present both in serum and CSF. Abs to P ribosomal proteins significantly correlated with psychosis (p=0.017), mononeuropathy multiplex (p=0.040), malar rash (p=0.004), serum anti-Sm Abs (p=0.042), and lupus anticoagulant (p=0.036). SLE onset age was significantly younger in patients with Abs to P ribosomal proteins. Logistic regression analysis confirmed the relationship between Abs to P ribosomal proteins and psychosis, malar rash, SLE onset age and lupus anticoagulant. CONCLUSIONS: Abs to ribosomal P proteins are associated with psychosis and might be associated with peripheral nervous system complications.


Subject(s)
Antibodies/immunology , Lupus Vasculitis, Central Nervous System/immunology , Ribosomal Proteins/immunology , Adolescent , Adult , Aged , Antibodies/blood , Antibodies/cerebrospinal fluid , Child , Cohort Studies , Female , Follow-Up Studies , Humans , Lupus Vasculitis, Central Nervous System/blood , Lupus Vasculitis, Central Nervous System/cerebrospinal fluid , Lupus Vasculitis, Central Nervous System/epidemiology , Male , Middle Aged
12.
Clin Rev Allergy Immunol ; 37(1): 36-43, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19016000

ABSTRACT

Atherosclerosis is a disease of the vascular wall, which predominantly affects large and medium-sized arteries. It represents a leading cause of morbidity and mortality in the Western world. In the last few decades, it has been clearly shown that immune system plays a relevant role in atherogenesis. The effectors of both innate and adaptive immunity, including immune cells, cell or soluble receptors, cytokines, chemokines, complement components or coagulation systems, and autoantibodies are able to modulate atherosclerosis. Among proteins belonging to innate immunity, the highly conserved pentraxin family, which encompass C-reactive protein (CRP), serum amyloid P (SAP), and the long pentraxin 3 (PTX3) seems to be directly involved in the induction and progression of atherosclerosis. By immunohistochemical staining, pentraxins were found within the atherosclerotic plaques where they could play a key role interacting with atherogenic-modified lipoproteins, favoring the formation of foam cells, and exerting a proinflammatory action. Pentraxin serum levels have been shown to be associated with clinical and subclinical atherosclerosis in general population. Antibodies against pentraxins have been demonstrated in patients with autoimmune diseases, but their role in atherogenesis is still controversial.


Subject(s)
Atherosclerosis/immunology , Autoantibodies , Autoantibodies/blood , Autoantibodies/immunology , Autoantigens/immunology , Autoimmunity , C-Reactive Protein/analysis , C-Reactive Protein/immunology , Humans , Immunity, Innate , Serum Amyloid P-Component/analysis , Serum Amyloid P-Component/immunology
13.
Autoimmun Rev ; 8(1): 24-8, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18703174

ABSTRACT

A growing body of experimental and clinical evidence supports the pivotal role of infections in the induction or exacerbation of systemic lupus erythematosus (SLE). Infections can be responsible for aberrant immune response leading to a loss of tolerance towards native proteins. Molecular mimicry, especially between Sm or Ro autoantigens and EBV Nuclear Antigen-1 response, as well as the over-expression of type 1 INF genes are among the major contributors to SLE development. On the other hand infections are very common in SLE patients, where they are responsible for 30-50% of morbidity and mortality. Several factors, either genetic, including complement deficiencies or mannose-binding lectin deficiency or acquired such as severe disease manifestations or immunosuppressant use, predispose SLE patients to infections. All types of infections, including bacterial, viral and opportunistic infections, have been reported and the most frequently involved sites of infections are the same as those observed in the general population, including respiratory, skin, and urinary tract infections. Some preventive measures could be adopted in order to reduce the rate of infections in SLE patients: i.e. screening for Mycobacterium tuberculosis and for some chronic viral infections before immunosuppressive treatment; adequate prophylaxes or drug adjustments when indicated, and pneumococcal and influenza vaccinations in patients with stable disease.


Subject(s)
Infections/etiology , Influenza Vaccines , Lupus Erythematosus, Systemic/complications , Molecular Mimicry , Chronic Disease , Epstein-Barr Virus Nuclear Antigens/immunology , Epstein-Barr Virus Nuclear Antigens/metabolism , Humans , Immune Tolerance , Immunosuppressive Agents/therapeutic use , Infections/immunology , Influenza, Human/immunology , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/mortality , Mass Screening , Mycobacterium tuberculosis , Pneumococcal Vaccines , Ribonucleoproteins/immunology , Ribonucleoproteins/metabolism , snRNP Core Proteins/immunology , snRNP Core Proteins/metabolism
14.
Clin Exp Rheumatol ; 26(1 Suppl 48): S8-11, 2008.
Article in English | MEDLINE | ID: mdl-18570748

ABSTRACT

Type 1 diabetes mellitus (T1D) and inflammatory bowel diseases (IBD) are multifactorial disorders of autoimmune origin. Several microbial agents have been reported to be associated with the development of type 1 diabetes and inflammatory bowel diseases in animal models by different mechanisms. These models which resemble the phenotype of the human disease they mimic, can be very useful to identify important pathogenetic mechanisms, as well as therapeutical targets to treat the disease. This review is focused on the immune inflammatory pathways which are considered to be associated with the pathogenesis T1D and IBD in transgenic mice.


Subject(s)
Diabetes Mellitus, Type 1 , Infections/complications , Infections/immunology , Inflammatory Bowel Diseases , Animals , Dendritic Cells/immunology , Dendritic Cells/microbiology , Dendritic Cells/virology , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/microbiology , Diabetes Mellitus, Type 1/virology , Disease Models, Animal , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/microbiology , Inflammatory Bowel Diseases/virology , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/microbiology , T-Lymphocytes, Regulatory/virology
15.
Clin Exp Rheumatol ; 26(1 Suppl 48): S18-26, 2008.
Article in English | MEDLINE | ID: mdl-18570750

ABSTRACT

In genetically predisposed individuals, viruses, bacteria, or parasitic infectious agents are suspected of inducing autoimmunity and/or exacerbating autoimmune rheumatic diseases (ARD) once self-tolerance is broken. Although direct evidence for this association is still lacking, numerous data from animal models as well as from humans support the hypothesis of a direct contribution of pathogens to the induction of several ARD. This review focuses on the possible role of infectious agents as triggers of autoimmunity in systemic lupus erythematosus, polymyositis-dermatomyositis, antiphospholipid antibody syndrome, and primary vasculitis. Indeed, vasculitis may be a clinical manifestation of an infectious disease (secondary vasculitis). In addition, immune response abnormalities and immunosuppressive medications may be responsible for the high percentage of infectious complications in ARD patients. Recent therapeutic approaches aimed at lowering doses of cytotoxic agents and shortening duration of treatment with the most toxic drugs, have proved to be as effective as conventional regimens. New drugs and strategies aimed at preventing infections could further improve the outcome of ARD patients.


Subject(s)
Connective Tissue Diseases , Infections/complications , Infections/immunology , Vasculitis , Connective Tissue Diseases/immunology , Connective Tissue Diseases/microbiology , Connective Tissue Diseases/virology , Humans , Vasculitis/immunology , Vasculitis/microbiology , Vasculitis/virology
16.
Clin Exp Rheumatol ; 26(1 Suppl 48): S1-7, 2008.
Article in English | MEDLINE | ID: mdl-18570747

ABSTRACT

It is thought that in genetically predisposed individuals, autoimmune diseases can be promoted and/or exacerbated by viruses, bacteria, or parasitic infectious agents. Pathogens can activate innate immune response interacting with Toll-like receptors that recognize pathogen-associated molecules. As a consequence of infections, a prolonged inflammatory response may occur leading to chronic inflammation with activation of adaptive immune response. In addition, the defective clearance of apoptotic infected cells, which progress- es to secondary necrosis, can foster the autoimmune reactions. Although numerous data from humans and/or animal models support the hypothesis of a direct contribution of pathogens to the induction of the disease, some infectious agents are able to prevent autoimmune disorders. In this review, data on the innate and adaptive immune response induced by pathogens are summarized, focusing on the possible protective or non-protective role of infections in the development of autoimmune diseases.


Subject(s)
Autoimmune Diseases/microbiology , Autoimmune Diseases/virology , Infections/complications , Infections/immunology , Rheumatic Diseases , Animals , Humans , Rheumatic Diseases/immunology , Rheumatic Diseases/microbiology , Rheumatic Diseases/virology
17.
Spinal Cord ; 46(4): 293-304, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17955034

ABSTRACT

STUDY DESIGN: Unrandomized trial. OBJECTIVES: To investigate the structural and functional relationships and the progression of muscle atrophy up to 20 years of spastic paraplegia. SETTING: Clinical follow-up in Vienna, Austria; muscle biopsies analyzed by light microscopy in Padova and by electron microscopy (EM) in Chieti, Italy. METHODS: Force was measured as knee extension torque; trophism by computer tomography scan; tissue composition and fiber morphology by histopathology and EM. RESULTS: In the long-term group of patients (17.0+/-2.6 years), force and size of thigh muscles were only slightly different from those of mid-term subjects (2.2+/-0.5 years). Histology and ultrastructure confirm that the difference in average size of muscle fibers between long-term and mid-term paralyzed leg muscles is actually very small. In addition, muscle fibers maintain the striated appearance characteristic of normal skeletal fibers even after 14-20 years of paralysis. Ultrastructural alterations of the activating and metabolic machineries, and the presence of fibers with lower motor neuron denervation features, may explain the low-force output and the reduced endurance of paretic muscles. CONCLUSION: The stable muscle atrophy that characterizes long-lasting spastic paraplegia suggests that there are no upper-time limits to begin a training program based on functional electrical stimulation.


Subject(s)
Muscular Atrophy/etiology , Paraplegia/complications , Paraplegia/pathology , Quadriceps Muscle/pathology , Spinal Cord Injuries/complications , Spinal Cord Injuries/pathology , Adult , Case-Control Studies , Female , Humans , Male , Muscle Strength/physiology , Muscular Atrophy/diagnostic imaging , Muscular Atrophy/pathology , Paraplegia/physiopathology , Quadriceps Muscle/diagnostic imaging , Quadriceps Muscle/physiopathology , Radiography , Spinal Cord Injuries/physiopathology , Thoracic Vertebrae , Time Factors
18.
Autoimmun Rev ; 7(1): 52-58, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17967726

ABSTRACT

It has been demonstrated that atherosclerosis (ATS) is enhanced in autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE). The reason for this accelerated process is still debatable and, although traditional risk factors are more prevalent in SLE patients than in general population, they do not seem to fully explain the enhanced risk. ATS has the characteristics of an autoimmune chronic disease, involving both the innate and the adaptive immunity. Moreover, it satisfies the four criteria defining an autoimmune disease, proposed by Witebsky and Rose. It has been shown that some autoantibodies, including anti-oxLDL, anti-beta(2)GPI, anti-HSP60/65, and more recently anti-oxLDL/beta(2)GPI, play a key role in the pathogenesis of ATS. However the role of these autoantibodies in accelerated ATS in SLE patients is still controversial. In fact, some of them seem to be proatherogenic and other protective; moreover, it has been demonstrated that induced oral tolerance has a protective role against ATS. We have recently observed that the levels of oxLDL/beta(2)GPI antigenic complexes and their antibodies were higher in patients with SLE than in healthy subjects, but we did not find a clear association between oxLDL/beta(2)GPI complexes and IgG or IgM anti-oxLDL/beta(2)GPI autoantibodies and subclinical ATS in SLE patients. Many other studies are required to explain the role of autoantibodies in the pathogenesis of ATS in SLE patients, because the characteristics of SLE seem to mask their effects for atherogenesis.


Subject(s)
Atherosclerosis/immunology , Autoantibodies/blood , Autoantigens/immunology , Lipoproteins, LDL/immunology , Lupus Erythematosus, Systemic/immunology , beta 2-Glycoprotein I/immunology , Antibodies, Antiphospholipid/blood , Antibodies, Antiphospholipid/immunology , Antigen-Antibody Complex/blood , Antigen-Antibody Complex/immunology , Antiphospholipid Syndrome/immunology , Atherosclerosis/physiopathology , Autoantibodies/immunology , Autoantigens/blood , Heat-Shock Proteins/blood , Heat-Shock Proteins/immunology , Humans , Immunity, Innate , Lipoproteins, LDL/blood , beta 2-Glycoprotein I/blood
19.
Clin Exp Rheumatol ; 25(3): 449-52, 2007.
Article in English | MEDLINE | ID: mdl-17631743

ABSTRACT

OBJECTIVE: To study anti-C1q antibodies in pregnant patients with systemic lupus erythematosus (SLE) and to evaluate their prognostic significance for the occurrence of disease flares or pregnancy complications. METHODS: Twenty-one pregnancies in 19 SLE patients prospectively followed were analyzed. Disease activity was evaluated on the basis of the physician's intention to treat and a modified version of the ECLAM index. Anti-C1q and anti-dsDNA antibodies were detected in the sera by an ELISA assay. Antinuclear antibodies, anti-ENA antibodies, anticardiolipin antibodies and lupus anticoagulant were also performed. RESULTS: In all the patients the disease was inactive at the beginning of the pregnancy. Four flares of disease activity were observed in 4 pregnancies (19%) and obstetric complications were encountered in 7 pregnancies (43%). Anti-C1q antibodies were positive in 4 (19%) pregnancies and anti-dsDNA antibodies in 8 (38%). The presence of anti-phospholipid antibodies at the first assessment was correlated with the occurrence of obstetric complications (p<0.05). The presence of anti-C1q and anti-dsDNA antibodies at the first assessment had no prognostic significance for the occurrence of flares or obstetric complications during the course of pregnancy. Although the small number of patients studied did not allow for statistically significant analysis, flares appeared to be more likely to occur in patients presenting with anti-dsDNA or anti-C1q antibodies during pregnancy compared to patients with no changes in these antibody titers (43% vs 8% respectively). CONCLUSIONS: The presence of anti-C1q and anti-dsDNA antibodies does not seem to be prognostic for the occurrence of flares during pregnancy. Further studies are warranted to explore this possibility.


Subject(s)
Antibodies, Anti-Idiotypic/blood , Complement C1q/immunology , Lupus Erythematosus, Systemic/immunology , Pregnancy Complications/immunology , Adult , Antibodies, Antinuclear/blood , Autoantibodies/blood , Female , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/physiopathology , Predictive Value of Tests , Pregnancy , Pregnancy Complications/blood , Pregnancy Outcome , Prognosis , Prospective Studies , Severity of Illness Index
20.
J Thromb Haemost ; 5(6): 1158-64, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17388963

ABSTRACT

OBJECTIVE: To evaluate the role of anti-prothrombin (anti-PT) antibodies in predicting thrombosis in patients with systemic lupus erythematosus (SLE). METHODS: An inception cohort of 101 SLE patients (12 males, 89 females; mean age 30 +/- 8 years), was considered. Clinical and laboratory evaluations were regularly performed during a 15-year follow-up (median 108 months) with a special focus on thromboembolic events. Serum samples were collected at time of diagnosis and at least once a year thereafter. IgG and IgM anti-PT, anti-cardiolipin (aCL) and anti-beta(2)glycoprotein I (beta(2)GPI) antibodies were measured by enzyme-linked immunosorbent assay (ELISA); lupus anticoagulant (LAC) was assayed by the dilute Russell's viper venom time and activated partial thromboplastin time tests. The analytical specificity of anti-PT ELISA was investigated. The timing of thrombosis occurrence was calculated using the Kaplan-Meier method. RESULTS: In the 15-year follow-up, thrombosis occurred in 14 out of the 101 patients: venous thrombosis in nine cases and arterial thrombosis in five. IgG and/or IgM anti-PT, anti-beta(2)GPI and aCL antibodies, and LAC activity were detected in ten, nine, seven, and nine cases, with sensitivity for thrombosis of 71.4%, 64.3%, 50% and 64.3%, respectively. Thrombosis-free survival was 90% at 5 years and 85.8% at 10 and 15 years, respectively. Thrombosis was predicted by anti-PT (P = 0.001), anti-beta(2)GPI antibodies (P = 0.002) and LAC activity (P = 0.001). Moreover, the risk of thrombosis progressively increased with the number of positive antiphospholipid antibody tests. The presence of four positive antibody tests was associated with a risk of thrombosis thirtyfold higher than in their absence. CONCLUSIONS: This longitudinal study shows that IgG anti-PT antibodies are predictors of thrombosis in SLE patients.


Subject(s)
Autoantibodies/blood , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/immunology , Prothrombin/immunology , Thrombosis/etiology , Thrombosis/immunology , Adolescent , Adult , Aged , Antibodies, Antiphospholipid/blood , Antibody Specificity , Cohort Studies , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Longitudinal Studies , Lupus Erythematosus, Systemic/blood , Male , Middle Aged , Risk Factors , Thromboembolism/blood , Thromboembolism/etiology , Thromboembolism/immunology , Thrombosis/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...